Brought to you by 
Evotec gets Alzheimer's disease candidates from Roche; concluded
08 Sep 2011
Executive Summary
Roche licensed Evotec AG (develops small molecules for CNS diseases) exclusive worldwide rights to its two Phase I compounds that will be used in combination with current therapies for Alzheimer's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Evotec gets Alzheimer's disease candidates from Roche; concluded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice